Among clopidogrel-based products on the international market, Plavix is one of the more broadly distributed brands, registered in 65 countries. Its active ingredient is clopidogrel, classified within the antiplatelet and antithrombotic category, and the page below sets out the structured regulatory data for the markets where the brand is authorised. This page is written for travellers, expatriates, and family members trying to identify Plavix abroad or recognise it on a local prescription.
Clopidogrel is prescribed in the management of cardiovascular conditions linked to arterial clot formation, including acute coronary syndrome, angina pectoris, the aftermath of a heart attack, cerebrovascular accident, and peripheral arterial disease. It also has a role in the context of coronary artery bypass graft procedures and unstable, accelerating angina. The full registered indication list, as recognised by national regulators, is shown in the structured section further down this page.
Because Plavix carries marketing authorisation across such a wide footprint — including Brazil, China, Belgium, Argentina, and the Czech Republic — travellers and expatriates frequently encounter the same medication abroad, sometimes under the Plavix label, sometimes as a clopidogrel generic produced locally. Packaging, prescription pathways, and reimbursement rules differ noticeably between regulatory regimes, and a pharmacist in the destination country is best placed to confirm whether a locally available clopidogrel product corresponds to what the patient takes at home.
Other molecules in the broader antiplatelet class are sold in many of the same markets under different active ingredients and brand names, but they are not interchangeable on a like-for-like basis. Any decision about starting, pausing, or substituting clopidogrel — whether triggered by travel, relocation, or a change in availability — belongs with a healthcare provider familiar with the patient's cardiovascular history.
